X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - New Drug Applications - 28/Aug 01:09

FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration...

Articles similaires

Sorry! Image not available at this time

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

drugs.com - 05/Sep 05:09

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Relief Therapeutics presents PKU GOLIKE study results at SSIEM 2024

pharmabiz.com - 03/Sep 00:00

Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...

Sorry! Image not available at this time

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

Sorry! Image not available at this time

Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?

zacks.com - 06/Sep 15:31

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sorry! Image not available at this time

Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?

zacks.com - 06/Sep 15:31

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sorry! Image not available at this time

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

haei.org - 03/Sep 17:29

KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...

Sorry! Image not available at this time

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

financialpost.com - 13/Sep 12:38

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...

Sorry! Image not available at this time

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

financialpost.com - 13/Sep 12:38

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...

Les derniers communiqués